GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Short Percentage of Float

Centessa Pharmaceuticals (STU:260) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Centessa Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Centessa Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centessa Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Short Percentage of Float falls into.


Centessa Pharmaceuticals (STU:260) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Short Percentage of Float
Comparable Companies
AMAM INBX PHVS ADPT KYMR RVNC COGT NVAX IMTX PRME OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CNTA:USA
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Website
https://www.centessa.com
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines